What would establish human rejuvenation?

Define the claim before looking at the result. “Human rejuvenation” can refer to a molecular change, recovery of tissue function or a reduction in later disease. Each requires a different experiment.

A programme could improve a damaged organ through a mechanism associated with ageing. Establishing that organ benefit would be a substantial result. A broader claim about slowing ageing across the body would require additional evidence about other functions, disease outcomes or the mechanism's reach.

Look for the intervention, population, comparison, outcome and observation period. Those details tell you whether the headline fits the study.

A biological effect is an early piece of evidence

In a small 2019 study of participants with diabetic kidney disease, researchers reported changes in markers associated with senescent cells after dasatinib plus quercetin. Tissue sampling addressed a mechanistic question in people. The uncontrolled design and size left clinical benefit unresolved.

Evidence that a therapy reaches cells and changes a target can explain how it works. The same study may have no reliable answer about whether participants feel or function better.

For a reprogramming intervention, a lower molecular age estimate should be considered alongside retained cell identity, tissue organisation and useful function. Researchers also need to examine unintended changes. The measurements should be selected because they test the mechanism or outcome claimed.

A favourable result from one measure can coexist with an unfavourable result elsewhere. Reporting the complete set protects readers from judging a programme by its best graph.

Benefit needs a comparison

Randomisation helps separate the effect of an intervention from differences between participants. Blinding can reduce the influence of expectations and assessment choices. The appropriate control depends on the intervention and the ethical constraints of the trial.

Functional outcomes can be selected for a particular system. A 2018 trial of TORC1 inhibition in older participants examined immune-related outcomes, including infections. It provides a more focused clinical question than the phrase “anti-ageing treatment” suggests.

A trial studying one age-related function can establish that result if its design and findings support it. It cannot automatically establish improved survival, lower cancer risk or regeneration elsewhere.

The size and uncertainty of the effect belong together. A statistical result should be reported with the comparison, confidence interval and outcome scale. A tiny change can become statistically detectable in a large sample without supplying the benefit implied by an expansive headline.

Durability, harms and independent tests

An intervention that produces a short-lived change has a different value and risk profile from one that produces lasting recovery. Follow-up should establish how long the effect persists and whether further exposure is required.

Uncommon harms require larger samples or continued surveillance. Some gene therapies can produce long-lasting biological changes, and FDA guidance addresses risk-based monitoring for delayed adverse events. A short tolerability report cannot close that question.

Independent replication can test whether a result depends on one laboratory, assay, participant selection or analysis decision. A replicated functional benefit provides stronger evidence than several related measurements from the original sample.

Ageing clocks add another test. The CALERIE methylation analysis showed that different clocks could respond differently to the same intervention. Agreement across measurements is useful, but the reason for agreement needs examination: several models can share inputs or training assumptions.

FDA materials explain why an observational biomarker association and a validated surrogate endpoint are different. Predicting who develops disease does not automatically establish that changing the marker through treatment will prevent it.

For a broad human rejuvenation claim, the strongest evidence would combine controlled functional improvements, supporting mechanistic findings, durable effects and an acceptable pattern of harms in the population studied. The required duration and sample depend on the benefit claimed.

A publication should also preserve negative results and protocol changes. A programme's evidence includes the tests it failed.

Ask what improved, compared with what, and for how long. Then use the name of that result.